L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo

[1]  Y. Nagasaki,et al.  A novel nitric oxide-based anticancer therapeutics by macrophage-targeted poly(l-arginine)-based nanoparticles. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[2]  L. Cui,et al.  L-Arginine supplementation in mice enhances NO production in spleen cells and inhibits Plasmodium yoelii transmission in mosquitoes , 2015, Parasites & Vectors.

[3]  Liang-ming Zhang,et al.  The therapy of gefitinib towards breast cancer partially through reversing breast cancer biomarker arginine. , 2015, African health sciences.

[4]  T. Ratliff,et al.  Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell–Mediated Control of T Cell Immunity , 2015, The Journal of Immunology.

[5]  P. Kearns,et al.  Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. , 2015, Blood.

[6]  Hong Zhao,et al.  Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer , 2015, Breast Cancer Research.

[7]  P. Thevenot,et al.  l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. , 2015, Cancer research.

[8]  P. Svider,et al.  iNOS Expression in CD4+ T Cells Limits Treg Induction by Repressing TGFβ1: Combined iNOS Inhibition and Treg Depletion Unmask Endogenous Antitumor Immunity , 2014, Clinical Cancer Research.

[9]  J. Fung,et al.  Cotransplantation With Myeloid-Derived Suppressor Cells Protects Cell Transplants: A Crucial Role of Inducible Nitric Oxide Synthase , 2014, Transplantation.

[10]  K. Schäkel,et al.  Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. , 2013, Cancer cell.

[11]  T. Fan,et al.  Estradiol increases ER-negative breast cancer metastasis in an experimental model , 2013, Clinical & Experimental Metastasis.

[12]  J. Markowitz,et al.  Myeloid-derived suppressor cells in breast cancer , 2013, Breast Cancer Research and Treatment.

[13]  S. Glynn,et al.  The yin and yang of nitric oxide in cancer progression. , 2013, Carcinogenesis.

[14]  P. Rodriguez,et al.  Metabolism of L-Arginine by Myeloid-Derived Suppressor Cells in Cancer: Mechanisms of T cell suppression and Therapeutic Perspectives , 2012, Immunological investigations.

[15]  C. Breuillard,et al.  Effects of a diabetes-specific enteral nutrition on nutritional and immune status of diabetic, obese, and endotoxemic rats: Interest of a graded arginine supply , 2012, Critical care medicine.

[16]  A. Sikora,et al.  Tumor-Expressed Inducible Nitric Oxide Synthase Controls Induction of Functional Myeloid-Derived Suppressor Cells through Modulation of Vascular Endothelial Growth Factor Release , 2012, The Journal of Immunology.

[17]  R. Kiessling,et al.  Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines , 2012, Cancer Immunology, Immunotherapy.

[18]  C. Kyriakopoulos,et al.  Myeloid-derived Suppressor Cells in Cancer Patients: A Clinical Perspective , 2012, Journal of immunotherapy.

[19]  L. Rivoltini,et al.  Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients , 2012, Cancer Immunology, Immunotherapy.

[20]  F. Marincola,et al.  IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. , 2011, The Journal of clinical investigation.

[21]  G. Wu,et al.  Effects of dietary l-arginine or N-carbamylglutamate supplementation during late gestation of sows on the miR-15b/16, miR-221/222, VEGFA and eNOS expression in umbilical vein , 2011, Amino Acids.

[22]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Wersto,et al.  Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. , 2011, Cancer research.

[24]  Yanping Zhang,et al.  The role of interleukin‐12 on modulating myeloid‐derived suppressor cells, increasing overall survival and reducing metastasis , 2011, Immunology.

[25]  M. Gad.  Anti-aging effects of l-arginine , 2010 .

[26]  S. Ostrand-Rosenberg.  Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity , 2010, Cancer Immunology, Immunotherapy.

[27]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[28]  R. Inman,et al.  Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis. , 2009, International immunology.

[29]  D. Getnet,et al.  Tumor Recognition and Self-Recognition Induce Distinct Transcriptional Profiles in Antigen-Specific CD4 T Cells 1 , 2009, The Journal of Immunology.

[30]  S. Ménard,et al.  FOXP3 expression and overall survival in breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Hui Yang,et al.  Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms. , 2009, Cancer letters.

[32]  H. Garbán,et al.  Regulation of apoptosis-related genes by nitric oxide in cancer. , 2008, Nitric oxide : biology and chemistry.

[33]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[34]  M. Amonkar,et al.  Assessing the economic burden of breast cancer in a US managed care population , 2008, Breast Cancer Research and Treatment.

[35]  P. Rodriguez,et al.  Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives , 2008, Immunological reviews.

[36]  D. Carbone,et al.  Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. , 2008, Cancer cell.

[37]  Xiaopeng Gao,et al.  l-Arginine Reduces Cell Proliferation and Ornithine Decarboxylase Activity in Patients with Colorectal Adenoma and Adenocarcinoma , 2007, Clinical Cancer Research.

[38]  A. Sica,et al.  Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.

[39]  D. Quiceno,et al.  L-arginine availability regulates T-lymphocyte cell-cycle progression. , 2007, Blood.

[40]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  R. Jain,et al.  The role of nitric oxide in tumour progression , 2006, Nature Reviews Cancer.

[42]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[43]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[44]  S. Signoretti,et al.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. , 2005, Cancer research.

[45]  T. Blankenstein.  The role of tumor stroma in the interaction between tumor and immune system. , 2005, Current opinion in immunology.

[46]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[47]  J. Brayer,et al.  Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.

[48]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[49]  M. Colombo,et al.  IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice1 , 2003, The Journal of Immunology.

[50]  J. Ochoa,et al.  Regulation of T Cell Receptor CD3ζ Chain Expression byl-Arginine* , 2002, The Journal of Biological Chemistry.

[51]  R. Bleackley,et al.  Cytotoxic T lymphocytes: all roads lead to death , 2002, Nature Reviews Immunology.

[52]  A. Frey,et al.  CD8+ Tumor-Infiltrating T Cells Are Deficient in Perforin-Mediated Cytolytic Activity Due to Defective Microtubule-Organizing Center Mobilization and Lytic Granule Exocytosis , 2001, The Journal of Immunology.

[53]  R. Steinman,et al.  Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. , 2001, The Mount Sinai journal of medicine, New York.

[54]  T. Tsuboi,et al.  Nitric oxide inhibits the development of Plasmodium yoelii gametocytes into gametes , 1998 .

[55]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[56]  A. Fulton,et al.  Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. , 1997, Cellular immunology.

[57]  B. Rowlands,et al.  Effect of Supplemental l-Arginine in a Chemical-Induced Model of Colorectal Cancer , 1996, World Journal of Surgery.

[58]  J. Yewdell,et al.  Effect of TAP on the generation and intracellular trafficking of peptide-receptive major histocompatibility complex class I molecules. , 1995, Immunity.

[59]  H. Sax.  Arginine stimulates wound healing and immune function in elderly human beings. , 1994, JPEN. Journal of parenteral and enteral nutrition.

[60]  J. Brittenden,et al.  Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy: effects of L-arginine supplementation. , 1994, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[61]  J. Brittenden,et al.  L-arginine stimulates host defenses in patients with breast cancer. , 1994, Surgery.

[62]  K. Black,et al.  Clinical trial of Serratia marcescens extract and radiation therapy in patients with malignant astrocytoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  A. Barbul,et al.  Arginine stimulates wound healing and immune function in elderly human beings. , 1993, Surgery.

[64]  J. Reynolds,et al.  Immunologic effects of arginine supplementation in tumor-bearing and non-tumor-bearing hosts. , 1990, Annals of surgery.

[65]  K. Tachibana,et al.  Evaluation of the effect of arginine-enriched amino acid solution on tumor growth. , 1985, JPEN. Journal of parenteral and enteral nutrition.

[66]  T. Tominaga,et al.  Inhibitory effect of L-arginine on growth of rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene. , 1975, Cancer research.

[67]  R. N. Bieter.  Report on the Meetings of the American Society for Pharmacology and Experimental Therapeutics, Memphis, April 21 to 24, 1937 , 1937 .

[68]  R. Wilcox,et al.  Myeloid-derived suppressor cells: therapeutic modulation in cancer. , 2012, Frontiers in bioscience.

[69]  J. Ochoa,et al.  Regulation of T cell receptor CD3zeta chain expression by L-arginine. , 2002, The Journal of biological chemistry.

[70]  A. Barbul.  Arginine and immune function. , 1990, Nutrition.

[71]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.